Pengyang Medical Secures Tens of Millions in Series B Funding to Accelerate Nationwide Remote ECG Diagnostic Service Platform

VCBeat (WeChat ID: vcbeat) has learned thatBeijing Pengyang Fengye Medical Equipment Co., Ltd. (abbreviated as: Pengyang Medical) — The Global Exclusive Provider of 18-Lead Dynamic ECG Products with Patented Technology and a Cardiovascular Diagnostic Service Platform, recently completed a tens-of-millions-yuan Series B financing round, led by Jiuwei Fund. Through this round of financing, Pengyang Medical will accelerate the market launch of multiple new products, as well as the establishment of remote ECG diagnostic service centers across provinces and cities in China and the coverage and operation of primary healthcare institutions, thereby accelerating the development of an authoritative cardiovascular diagnostic service platform in China. Previously, the company secured a tens-of-millions-yuan Series A financing round from CCB Medical Growth Fund.

Pengyang Medical specializes in technological innovation, as well as the research and development, manufacturing, and sales of products within the cardiovascular field. The company has developed a range of intelligent monitoring and AI-driven diagnostic product lines, represented by its globally exclusive patented product—the 18-lead ambulatory ECG analysis system. Seven of its products have obtained NMPA certification, three have received CE certification, and 31 additional products are currently under development or regulatory review. As one of the few high-end manufacturers possessing world-leading original technologies and strong capabilities in product commercialization, Pengyang Medical is recognized as a National High-Tech Enterprise and a Beijing “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise.

Pengyang Medical is the only enterprise awarded the title of “18-Lead Ambulatory ECG Technology R&D Base” by the Chinese Society of Electrocardiology; it is a founding member of the China County-Level Medical Community Alliance and an industry-standard enterprise for the National Traditional Chinese Medicine Cardiovascular Standardized Diagnosis and Treatment Center. The “Pengyang ECG Intelligent AI Diagnostic System” won first prize in the 2018 National Medical Artificial Intelligence Competition, and the “18-Lead Ambulatory ECG Diagnostic System” won first prize in the 4th China Medical Device Innovation and Entrepreneurship Competition in 2021. In 2021, the “Expert Consensus on 18-Lead Ambulatory Electrocardiography” was published in the authoritative industry journal *Chinese Journal of Cardiovascular Research*.

Pengyang Medical has consistently adhered to an innovation-driven development strategy propelled by the dual engines of technology and market expansion. To date, the company’s products have been granted five national invention patents, 11 utility model patents, and 26 computer software copyrights, with plans to continuously build a patent pool comprising over 100 items in the future. Currently, Pengyang Medical’s products have been adopted by more than 100 Grade IIIA hospitals, including four of the top eight hospitals specializing in cardiovascular care. The company has also collaborated with numerous Grade IIIA hospitals across China to establish multiple remote ECG diagnostic centers, covering thousands of medical institutions. By leveraging a model that integrates specialized products, expert diagnostics, and operational services, Pengyang Medical provides comprehensive, professional, and timely full-cycle management services—including cardiovascular disease screening, diagnosis, and rehabilitation follow-up—to primary healthcare institutions and patients. Over the next three years, the company aims to cover 50,000 institutions, connect with 200,000 physicians, and serve 12 million patients, striving to become China’s most authoritative and medically valuable cardiovascular diagnostic service platform.

With outstanding capabilities in technological innovation, business model innovation, academic promotion, and market expansion, Pengyang Medical possesses significant growth potential and has attracted considerable attention from investors. Leveraging its strong product competitiveness and effective market operations, the company has achieved profitability. The company’s designation as a “Beijing Specialized, Refined, Differential, and Innovative Enterprise” in 2021 has further accelerated its IPO process.

Wang Songliang, a partner at Jiuwei Fund, stated that the fund continues to focus on investment opportunities in the field of innovative medical devices. With the advent of an aging society in China, Pengyang Medical, which possesses certain technological barriers in the field of cardiovascular diagnosis, is expected to achieve rapid growth.